Tag: Kura Oncology
March 5, 2019
Kura Oncology Announces FDA Clearance of Investigational New Drug Application for Menin-MLL Inhibitor KO-539
Kura Oncology (NASDAQ:KURA) has announced that the US Food and Drug Administration (FDA) has cleared the company’s investigational new drug... January 18, 2019
Kura Oncology Reports Clinical Activity of Tipifarnib in Subsets of Pancreatic Cancer Associated with High CXCL12 Expression
Kura Oncology (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, reported new findings identifying...
October 22, 2018
8 Top Gains and Losses at 2018’s ESMO Event
Big Pharma players and smaller oncology-focused companies alike were among the presenters at the annual meeting, which runs from October... October 22, 2018
Kura Oncology Presents Update on Positive Phase 2 Trial of Tipifarnib in HRAS Mutant HNSCC and Preliminary Results in HRAS Mutant SCC
Kura Oncology (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today reported updated preliminary... June 28, 2018
Kura Oncology Announces Commencement of Public Offering of Common Stock
Kura Oncology (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, announced that it has... May 9, 2018
Kura Oncology Reports First Quarter 2018 Financial Results and Provides Corporate Update
Kura Oncology (Nasdaq:KURA) a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today reported first quarter...
April 29, 2018